| Autor: |
Saika W; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Kawahara M; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Tashiro H; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Teramoto Y; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Nagai S; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Kumode M; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Iwasa M; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Asai A; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Fujishiro A; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Nishimura R; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Minamiguchi H; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Moritani S; Department of Clinical Laboratory Medicine and Diagnostic Pathology, Shiga University of Medical Science., Kito K; Department of Medicine (Division of Hematology), Shiga University of Medical Science., Andoh A; Department of Medicine (Division of Hematology), Shiga University of Medical Science. |
| Abstrakt: |
Venetoclax, a selective BCL-2 inhibitor, is prescribed clinically for acute myeloid leukemia (AML) treatment. However, it is unclear if known chromosomal or genetic abnormalities associated with AML also influence BCL-2 expression. Few studies have examined BCL-2 expression in AML-related precursor neoplasms such as primary myeloid sarcoma (MS) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). In this study, we examined BCL-2 expression using immunohistochemistry in 7 patients with AML, who also carried genetic and chromosomal abnormalities typical to AML including t (8;21), t (15;17), FLT3-ITD mutation, and complex karyotype, along with 1 patient with primary MS and 3 patients with BPDCN. As a result, expression of BCL-2 was observed in all patients with AML and 1 patient with primary MS. In the patients with BPDCN, BCL-2 was highly expressed in all regions with evidence of tumor cell infiltration, such as skin, bone marrow, and lymph node. These results could be used as evidence in the support of administering venetoclax to adverse-risk patients with AML, MS, or BPDCN. |
